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THE ASSUMPTION THAT, IF TWO measurements are not significantly different, one can conclude that they are equal is a widely prevailing misconception, since all that has been shown is absence of evidence of a difference (3) . Hence a simple inversion of the null hypothesis to create a statistical test for equivalence is not valid. We therefore designed a novel method to determine the level of gene expression equality in a microarray experiment. This method calculates the maximum difference in expression level of a gene, based on the estimated confidence interval on that gene's expression variance. We normalized these differences to the minimum expression levels and listed the genes by equivalence ranking relative to their expression level. A false discovery rate (FDR) estimation was used to determine significance.
Currently, a wide range of functional properties have been ascribed to macrophages, such as elimination of pathogens through receptor-mediated phagocytosis and killing of tumor cells through production of TNF-␣, proteinases, and reactive oxygen species (16, 17) . Macrophages can also regulate the adaptive immune system by MHC class I-and II-mediated antigen presentation and production of cytokines and chemokines (24) . This immune regulation can be subdivided into classic (M1) and alternative (M2) activation, of which the exact phenotypic characterization is a current topic of investigation (47) . The regulation of these processes is largely dependent on microenvironmental stimuli and may thus vary between macrophages originating from different tissues. As macrophages also play an important role in atherosclerotic plaque initiation and progression (33) , heterogeneity in atherosclerotic plaque macrophages and their precursors the monocytes is studied intensively in atherosclerosis research (15, 17, 43, 44) . Apart from detecting differences in expression profiles, the comparison of the transcriptomes of different macrophage subpopulations may also provide valuable information to define molecular similarities. We therefore hypothesized that macrophages from atherosclerotic plaques and macrophages isolated from three nonatherosclerotic tissues share a common expression profile.
We have determined the expression patterns of human Kupffer cells and alveolar, splenic, and atherosclerotic plaqueresiding macrophages and analyzed the transcriptomes for the presence of gene sets that have equivalent expression levels in all macrophage subsets. To achieve this a new statistical approach in microarray data analysis had to be developed.
We applied our new method and identified a subset of 500 genes that have equivalent expression levels in macrophages within each patient. We analyzed this set of genes using DAVID: Database for Annotation, Visualization, and Integrated Discovery (9) and Ingenuity Pathway Analysis (Ingenuity Systems, http://www.ingenuity.com). Of all interrogated known macrophage markers, CD68 was the only marker present in the macrophage gene set. All macrophage isolations were based on CD68 positivity, and thus the presence of CD68 in the gene set forms a proof of concept. Hierarchical clustering of the expression levels of these 500 equivalently expressed genes in the Novartis human gene expression atlas (42) revealed a subset of 200 genes that are specifically expressed in macrophages.
To demonstrate the added value of integrating equivalently expressed genes in pathway analysis of differential expression experiments, we combined both significantly (P Ͻ 0.01) upregulated and downregulated genes, with the gene set of 500 most equivalently expressed genes in Ingenuity pathway analysis. This revealed a network containing several endoplasmic reticulum stress (ER stress)-related genes that were upregulated in carotid plaque macrophages, whereas xbox binding protein 1 (XBP1), an inducer of ER stress, was among the nonregulated ER stress-related genes. This network was not detected using solely up-or downregulated genes and shows that the ER stress response in plaque macrophages is induced, but not all known ER stress-related mediators are transcriptionally activated. These results demonstrate the added value of the integration of expression equivalence in pathway analysis.
MATERIALS AND METHODS
Tissue samples for microarray analysis. Fresh atherosclerotic (carotid arteries) and nonatherosclerotic (lung, liver, and spleen) tissues were obtained at autopsies (n ϭ 4) within 24 h after decease. Our protocols, including collection, storage in the Maastricht Pathology Tissue Collection, and use of tissue and patient data, were reviewed and approved by the Federation of Dutch Medical Scientific Societies ("Code for Proper Secondary Use of Human Tissue in the Netherlands," http://www.fmwv.nl).
None of the patients had any clinical symptoms of systemic inflammation or malignancies. Detailed patient characteristics are shown in Supplemental Table S1 . 1 Immediately after resection, tissues were divided into four parallel parts for histological analysis, RNA quality assessment, and macrophage isolation. Tissue parts destined for histological analysis were embedded in paraffin, while parts for RNA quality assessment were immediately frozen in liquid nitrogen and stored at Ϫ80°C. The carotid samples were directly transferred into ice-cold phosphate-buffered saline (PBS) and then frozen in Tissue-Tek OCT compound (Sakura Finetek Zoeterwoude, the Netherlands) in liquid nitrogen-cold 2-methylbutane. The lung, liver, and spleen tissues were directly put into ice-cold calcium magnesium-free Hanks' buffer (Invitrogen, Carlsbad, CA) and kept on ice until use.
The stage of atherosclerosis was determined according to Virmani et al. (49a) based on hematoxylin-eosin (HE)-stained paraffin sections. The localization of macrophages was assessed after anti-CD68 immunohistochemical staining. Only carotid arteries with stable lesions (thick fibrous cap atheroma) were used in microarray analysis.
To evaluate RNA quality of the tissues before macrophage isolation, total RNA of slices of whole tissue was isolated using a combination of TRIzol reagent (Invitrogen) and RNeasy mini kit (Qiagen, Valencia, CA). RNA integrity of the tissues was evaluated using Agilent's 2100 Bioanalyzer System and RNA 6000 Nano LabChip Kit (Agilent Technologies, Palo Alto, CA). Patients were included for microarray analysis only if the RNA integrity value of each tissue was Ͼ6.
Macrophage and macrophage RNA isolation. Atherosclerotic macrophages were isolated by laser capture microdissection (LCM, Arcturus Pixcell II) from 6 to 10 consecutive frozen sections (2,000 pulses per lesion) using CD68-immunopositivity on parallel sections as a navigator. LCM was performed on 5-m-thick OCT-frozen sections. Sections were fixed in iced-cold acetone and counterstained with hematoxylin and dehydrated in graded ethanol and xylene. Macrophages were harvested from the macrophage-rich shoulder areas.
Nonatherosclerotic macrophages were isolated using immunomagnetic beads coated with CD68 mouse anti-human antibody (Santa Cruz Biotechnology, Santa Cruz, CA) using CELLection Pan Mouse IgG Kit (Dynal Biotech, Oslo, Norway) according to the manufacturer's protocol. In brief, fresh tissues obtained during autopsy were collected in ice-cold calcium magnesium-free Hanks' buffer (Invitrogen). Cell suspensions were obtained by passage through RNase-free nylon membrane (BD Falcon, San Jose, CA) and were washed twice in ice-cold RNase-free calcium magnesium-free PBS buffer (CMF-PBS, pH 7.2). Cell pellets were then resuspended in ice-cold CMF-PBS (pH 7.2) contained 0.1% BSA and 2 mM EDTA. The CD68 antibodycoated beads were used to separate the macrophages from the cell suspensions. After separation the macrophages were removed from the cell suspensions by repeated washing on a magnet (Dynal MPC, Dynal Magnetic Particle Concentrator, Dynal Biotech) and were subsequently released from the beads with a releasing buffer containing DNase (Boehringer Mannheim, Mannheim, Germany).
Macrophage total RNA was isolated using the Absolutely RNA microprep kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol. DNA was removed by using 50 U DNase (Qiagen). RNA concentration was determined using the NanoDrop ND-1000 Spectrophotometer (NanoDrop, Wilmington, DE). Furthermore, availability of macrophage RNA after LCM was determined by ␤-actin RT-PCR.
To exclude a bias from the separate macrophage isolation techniques we tested the differences in the expression levels of macrophage and smooth muscle cell representative genes between LCM and immunomagnetic bead-isolated macrophages. No significant differences were observed, indicating that differences in the macrophage isolation procedure did not introduce a bias in the expression profile (Supplemental Fig. S1 ).
Array hybridization and analysis. We performed microarray analysis of in total four types of tissue macrophages i.e., Kupffer cells and atherosclerotic plaque, splenic, and alveolar macrophages from a total of four patients. Patients were included only when the same patient could provide quality RNA of all four macrophage types. All 16 RNA samples were analyzed using duplicate arrays consisting of technical replicates. In total we performed 32 microarrays.
Total RNA of ϳ2,000 cells of LCM-derived atherosclerotic macrophages and 30 ng of nonatherosclerotic macrophage RNA was amplified two rounds using the RiboAmp RNA Amplification Kit (Arcturus, Mountain View, CA). Up to 1 g of antisense amplified RNA (aRNA) samples was labeled with aminoallyl-rUTP (Sigma) during a third round of amplification using the T7-based Ambion MessageAmp kit (Ambion, Huntingdon, UK). Aminoallyl-modified amplified RNA was labeled with either Cy3 (common reference sample) or Cy5 (samples) monoreactive dyes (GE Healthcare, Uppsala, Sweden). Labeled aRNAs were applied in duplicate to custom made 65 mer oligonucleotide arrays representing 18,658 unique genes (Sigma-genosys/Compugen library) against an equal amount of common reference sample. The common reference cRNA sample comprised equal quantities of RNA from the following three cell types and tissues 1) human umbilical cord endothelial cells stimulated with TNF-␣ (50 g/ml, 6 h); 2) THP-1 cell line incubated for 24 h with phorbol myristate acetate (100 g/ml) and subsequently for 6 h with lipopolysaccharide (1 g/ml); and 3) a mix of whole-mount human aorta and carotid artery. Images were acquired using the Agilent-II scanner (Agilent Technologies) and feature extraction was performed using ArrayVision 8.0 software (GE Healthcare Europe, Diegem, Belgium). Background-subtracted intensities were Loess-normalized (Limma package, Bioconductor software, http://www.bioconductor.org). 1 The online version of this article contains supplemental material.
Next, the measurements of each pair of replicated experiments were combined in an error-weighted manner. To this end, the log-ratio measurements per gene were weight-averaged, with a weighting factor inversely proportional to the reported variance of the measurement as described by Weng et al. (53) . Furthermore, the intensity values were also combined by first scaling the measurements of both arrays for each patient-tissue combination such that they give the same average gene intensity for the common reference, and secondly taking the average intensity for each gene in each patient-tissue combination.
We additionally performed differential expression analysis on the expression data, to study the possibilities of combining equivalently expressed genes with differentially expressed genes in pathway analysis. To do so we determined differential expression in plaque residing macrophages by using a two-step selection process, to reduce the effect of interpatient variability of the analysis and to identify the changes that are truly due to the differences in macrophage phenotype. Firstly, genes differentially expressed in plaque residing macrophages compared with Kupffer cells and alveolar and splenic macrophages were identified through intrapatient comparisons assessing significantly regulated (P Ͻ 0.01, Rosetta ratio-error model for gene expression analysis) genes in plaque macrophages compared with macrophages from each tissue separately (53) (i.e., plaque macrophages vs. splenic macrophages, plaque macrophages vs. Kupffer cells, and plaque macrophages vs. alveolar macrophages). The analysis was performed using Rosetta Biosoftware (Seattle, WA). Secondly, the genes that were differentially expressed in all three intrapatient-tissue comparisons as consistently up-or downregulated in atherosclerotic macrophages were selected. All genes that were selected in the single patient comparisons were combined. A total of 1,614 genes were selected, of which 715 were downregulated in plaque macrophages compared with the other macrophages and 899 were upregulated.
The microarray data sets have been submitted to the Gene Expression Omnibus database under accession number GSE7074 (http:// www.ncbi.nlm.nih.gov/geo/).
Equivalence test. As mentioned in the introduction, equivalence testing is not simply applying a differential test and then claiming equivalence if no significant difference is observed. Instead, in an equivalence test of a difference D, the null hypothesis (for the symmetric case) is given by H 0 :|D| Ͼ ε; i.e., D Ͻ Ϫε or D Ͼ ε and the alternative hypothesis is given by H 1 :|D| Յ ε; i.e., Ϫε Յ D Յ ε. Here, ε indicates the margin within which a difference is considered negligible (28 After the preprocessing steps our macrophage gene expression set consisted of a log expression ratio xptg for each patient p ϭ 1, . . . ,4, for each tissue type t ϭ 1, . . . , 4, and each gene g ϭ 1, . . . , 18,658. Furthermore, a log ratio error estimate ptg based on the propagation noise (estimate of the noise on an array using pixel variations) and the scatter noise (variation between the technical replicates) was obtained from the data. This information was used to determine a measure that indicates to what extent the expression of a gene varies over the different macrophage subsets within an individual patient. To do so, we looked at pair-wise differences xptg Ϫ xpt=g for each pair t, t= of tissue types, and determined their confidence interval, as discussed above, based on the corresponding standard error
k ␣ depends on the confidence level, as mentioned before. Next, a confidence limit was determined on the absolute difference for each gene and each patient, given by ⌬pg ϭ maxt,t=(|xptg
2 ), which we termed the "per patient gene spread."
This corresponds to the minimal value for the margin ε for which the null hypothesis of equivalence testing is rejected. Taking the maximum ⌬ g ϭ maxp ⌬pg over all patients then gave a measure for the variability of each gene, which we termed the "(overall) gene spread." Note that for a small gene spread, the average gene expression level may differ between different patients, as long as within the same patient the measurements are close.
The gene spread ⌬ g in itself is not enough to identify genes that are equivalently expressed. The reason for this is that genes that are hardly expressed will also tend to have low ⌬ g values. Hence we have to take the absolute expression levels of the genes into account. To obtain some insight into how these parameters are influenced by random chance, two types of random permutation experiments were performed:
In the first experiment, the measurements were randomly permuted over the genes for one certain tissue type at a time, from all four patients.
In the second experiment, the measurements were randomly permuted over the genes for all four tissue types from one single patient at a time.
The first experiment was performed for each of the tissue types, and the second one for each of the patients. Furthermore, all permutation experiments were repeated 100 times. In total this thus resulted in 800 random permutation tests. Plotting the gene spread against the intensity of the randomized data showed that the gene intensity plays an important role in discriminating experimental values from values based on random chance (Fig. 1A ). This plot hence motivates the incorporation of the gene intensity into the equivalence test.
To this end, the intensity values I ptg of each patient-tissue combination had to be normalized by scaling the separate microarrays such that they resulted in the same average gene intensity for the common reference. Next, the average over all tissue types and the minimum over all patients was taken, resulting in a gene intensity
With this minimum gene intensity and the gene spread, a "relative gene spread" was calculated, given by
Note that the logarithm of the intensity was taken, as the gene spread is also in the logarithm domain. Now the genes can be sorted in order of increasing relative gene spread, and we can apply a cut-off value t below which we call a gene "equivalently expressed." This results in a cut-off line in the log gene intensity vs. gene spread space, as indicated in Fig. 1B . The slope of the line equals 1/t, and the points left of the line correspond to genes with a smaller relative gene spread than t.
FDR. Given a cut-off value t, a number d of genes is identified as equivalently expressed. A certain fraction of this number, however, has been identified by chance. To obtain some insight into how many genes are falsely identified, the two random permutation experiments were performed and the fraction f was determined of the m ϭ 18,658 genes that was identified as equivalently expressed in these random permutation experiments. As these experiments should not return any equivalently expressed genes, this fraction of genes was identified by random chance.
Given the number d of identified genes for cut-off value t, the fraction of falsely discovered genes of the d genes was determined as follows. First, the truly identified genes were denoted by td and the falsely identified ones by fd, i.e., d ϭ td ϩ fd. Given that td genes were truly equivalently expressed, and assuming that all m Ϫ d notidentified genes were truly nonequivalently expressed, we expected A: gene intensity is plotted against the gene spread to show the effects of the two permutation approaches on the false discovery rate (FDR). If all samples in all patients are permuted, a torpedo-like shape is notable (yellow). If all samples of 1 patient are permuted the cloud shifts toward higher gene spread and decreases the log gene intensity of the genes (blue) compared with the original data. Permutation of 1 sample in all patients results in a similar shape as seen in the original data in which the gene spread increases but the log gene intensity is not strongly affected (green). The original data (red) has a distinct set of genes that have a low gene spread and a high gene intensity. B: log gene intensity vs. gene spread box plots of all genes. A cut-off purely based on the relative gene spread is not prone to this effect and fitted our model well based on the shapes of the permuted clouds. This results in 500 positive genes with a slope of 3.27 and an FDR of 5.5% at confidence level alpha ϭ 0.05. The distance to the cut-off line represents the distance that is indicated by the black arrow. C: inclusion of an offset in the cut-off function results in an unequal distribution of the positive genes. The lines represent the optimal offset and slope at different numbers of claimed positives. Genes in the yellow plane are positive at a lower number of claimed positives and thus at a lower FDR but become negative with an increasing FDR. D: FDR (%) vs. number of claimed positives plots. The lower panel is a zoomed-in scale version of the upper panel (E). The use of different confidence intervals has no significant effect on the FDR up to 600 genes. If Ͼ600 genes are selected, the ␣-level increasingly affects the FDR percentage. The average FDR percentage at ϳ500 genes is 5%. The FDR is dependent on the used permutation method. The FDR percentages of 2 permutation methods are shown; either all samples permuted in 1 patient (1p4s) or 1 sample permuted in all patients (4p1s). Permuting 1 sample in all 4 patients generally results in a 1% higher FDR estimate.
With this, fd ϭ d Ϫ td can be computed, with which an FDR ϭ fd/d was determined.
Cut-off function. The cut-off value t on the relative gene spread results in a separating line in the log gene intensity vs. gene spread plane that runs through the origin, with slope 1/t. It is worth investigating the model's performance if the line crosses the vertical axis at another point, at a height o. Hereto the offset o first needs to be subtracted from the log I g value before the division, resulting in a "shifted relative gene spread," given by
A cut-off line to obtain a certain number d of identified genes can now be determined by optimizing over the choices for o and t, in such a way that a minimal FDR is achieved. Figure 1C shows the optimal choice of offset o and slope (1/t) for different values of d. Given a number d of identified genes, the genes can be sorted in order of increasing S g, but alternatively, they can be sorted in order of decreasing distance to the cut-off line.
After determining the optimal cut-off line for each number d of identified genes, we can plot a graph of the FDR vs. the number d, as shown in Fig. 1D . We see that the FDR at 500 discovered genes it is ϳ5-6% and that the used confidence level has no significant effect on the FDR up to 600 genes.
Hierarchical clustering. Hierarchical clustering and visualization of the expression levels of the 500 most equivalently expressed genes in 79 human tissues were performed using Eisenlabs Cluster and Treeview software packages (11) . The Novartis Human U133A gcRMA-condensed data were obtained from the download section of the Novartis website. This dataset consists of transcription profiles of 79 different human tissues varying from 1 to 4 replicates per tissue as previously described by Su et al. (42) . The data of each tissue were median centered by the cluster package prior to centered hierarchical clustering.
Pathway analysis. The 500 most equivalently expressed genes ranked on the relative gene spread were submitted to pathway analysis. This was performed either by using DAVID (9) or the Ingenuity Pathway Analysis (Ingenuity Systems, http://www.ingenuity.com) system. The 500 most equivalently expressed genes were uploaded to the DAVID web-based application, and the results were obtained from the functional annotation chart.
The 500 most equivalently expressed genes were also uploaded into the Ingenuity Pathway Analysis software and were analyzed without applying any cut-offs in the analysis steps. In addition the 500 most equivalently expressed genes were combined with the 1,614 differentially expressed genes in the same set of tissues. Before inputting the data into Ingenuity Pathway Analysis, we ascribed the upregulated genes a fold change code of 1 for the upregulated, Ϫ1 for the downregulated and 0 for the equivalently expressed genes. In the Ingenuity output file shown in Fig. 2A we manually colored the equivalently expressed genes yellow, instead of the light red color given to them by the Ingenuity software.
RESULTS

Gene spread.
To determine the level of expression equivalence per gene the per patient gene spread was calculated. This was performed for each gene in each patient individually. Per gene the average gene expression value and a confidence limit in each type of macrophage were calculated per patient. The overall gene spread was then determined at different confidence intervals. An increase in confidence interval in our method adds more weight to the variance of a gene.
An equivalence ranking can be made by ranking the genes based on the gene spread value. From this ranking a top 500 of genes can be extracted that are most equivalently expressed over the separate macrophage types. The composition of this top 500, however, is influenced by the confidence interval used in determining the gene spread. The reason for this is that the gene spread not only depends on the difference in the measurements across the four tissues of origin, but also on the errors of the measurement, as one can see from the formula of the per patient gene spread. A very strict ␣-level (i.e., 0.005) hence adds more weight to the technical error of the measurement compared with a less strict ␣-level (i.e., 0.1). So, a gene with higher measurement errors will drop down in the top 500 list when the level ␣ is decreased.
Considering only the gene spread as a measure of expression equivalence results in a ranking, in which 349 out of the 500 most equivalently expressed (70%) genes are independent of the used level ␣ (Fig. 2B) . Inclusion of the log intensity in ranking the genes, through calculating the relative gene spread, decreases the effect of the applied ␣-level. The absolute measurement error is higher at high intensity values, which justifies inclusion of the intensity values in the equation. Ranking the genes after correction for intensity yields 389 out of the 500 most equivalently expressed genes (78%) at each of the applied ␣-levels (Fig. 2B) . Gene ranking, however, varies with different ␣-levels. In addition, the number of genes that are only among the top 500 listed genes at a certain level is greatly reduced (i.e., 0 genes at a level of ␣ ϭ 0.05) by including the gene intensity. Because all genes that are ranked using a level of ␣ ϭ 0.05 are also present in the top 500 ranked genes of either ␣ ϭ 0.1, ␣ ϭ 0.025, or ␣ ϭ 0.005, we determined that interval level of ␣ ϭ 0.05 was most suitable for our dataset.
Randomization through permutation. As a measure of statistical significance in equivalence we applied an FDR estimation by permuting the data. All permutations were repeated 100 times. In each repeat a different sample (1st method) or patient (2nd method) was permuted. If all samples in all patients were permuted, a torpedo-like shape was notable (Fig. 1A) . If all samples of one single patient were permuted, the original data cloud shifted toward higher gene spread and decreased log gene intensity of the genes. Permutation of data from one tissue sample in all patients resulted in a similarly shaped data cloud as seen for the original data in which the gene spread increases, but the log gene intensity was only marginally affected (Fig.  1A) . To incorporate these different effects of randomization in our model we averaged the outcome of the two methods.
Optimization of the cut-off. Determining a subset of genes with equivalent expression levels in macrophages from all tissue types requires a cut-off. Genes with significantly equivalent expression levels were identified using the FDR estimate as a means to determine an optimal cut-off on the relative gene spread. Selecting all genes with a relative gene spread below a threshold t then means selecting the genes with a point above the line with slope 1/t. We tested the performance of the model after introduction of an offset o into the cut-off function to fit the data. For each number of genes an optimal combination of slope and offset with a minimal FDR was calculated. A few of these lines that were calculated at a level of ␣ ϭ 0.005 are shown in Fig. 1C . Inclusion of an offset in the cut-off function renders the significance of equivalence of a gene independent of the used FDR estimate, due to the linearity of this function, especially at very strict ␣-levels. This means that some genes that are called equivalent at lower FDR come to lie below the optimal threshold with an increasing FDR (Fig. 1C) . Thus a very stringent threshold analysis would include genes that would have been excluded at a less stringent threshold. This effect depends on the used ␣-level. Contrary to ␣ ϭ 0.005, a level of ␣ ϭ 0.05 shows no genes in this particular experiment that lose their significant equivalence with an increasing FDR up to 5%. At higher FDR estimates or in other experiments this effect will probably also occur. We prefer to use a cut-off purely based on the relative gene spread, because it is rather refractory to changes in FDR and thus results in more robust results. Moreover, it is most resistant to permutation type and thus fits our model best. This strategy resulted in 500 positive genes with a slope of 3.27 and an FDR of 5.5% at ␣ ϭ 0.05. Figure 1E , depicting the average FDR percentage plotted against the number of significantly equivalently expressed genes, shows a 5% FDR at ϳ500 genes. Again the use of different ␣ levels has no significant effect on the FDR up to 600 genes. If Ͼ600 genes are selected, the chosen ␣-level will affect the FDR percentage. The FDR, however, is dependent on the permutation method used. Permuting one sample in all four patients generally resulted in a 1% higher FDR estimate compared with permuting all samples in one patient. This suggests the need to average the outcome of both FDR estimates.
Ranking of the genes. The equivalently expressed genes can be ranked by gene spread, relative gene spread, or distance to the cut-off function. The 500 most equivalently expressed genes at ␣ ϭ 0.05 are ranked by distance to the cut-off function (Supplemental Table S2 , Fig. 1B ). The expression of these genes is marked as significantly equivalent in macrophages from carotid plaques, liver, lung, and spleen within each patient. The cut-off function and the corresponding data are shown in Fig. 1B . We checked the distribution of known macrophage markers and found them to be spread throughout our data set. We found one macrophage marker with significant The XBP-1 pathway is an example of the added value of combining equivalence data with differential expression data in pathway analysis. B: Venn diagram of the overlapping genes in the 500 most equivalently expressed genes using different ␣-levels in calculating the gene spread. Solely considering the gene spread (left), relatively large numbers of genes are specific for each ␣-level. Inclusion of the log intensity in ranking the genes, through calculating the relative gene spread (right), decreases the effect of the used ␣-level. At ␣ ϭ 0.05 no genes and at ␣ ϭ 0.025 5 genes are specific for that level. The results for ␣ ϭ 0.10 and ␣ ϭ 0.005 still have higher numbers of specific genes, i.e., 38 and 41, respectively. expression equivalence, CD68 (rank 49). All other macrophage markers, such as F4/80, MAC-3, CSF-1R, and lysozyme M, were not equivalently expressed (Supplemental Table S3 ).
Pathway analysis. We summarize some of the equivalently expressed genes that are remarkable given their alleged functional role in dedicated macrophage subsets, CD68, TICAM1, CD1C, VEGFB, IL1RN, NOS3, insulin-like growth factor-II, APOC2, ABCG4, and their function in Table 1 .
In addition we analyzed the equivalently expressed genes using DAVID (9) and identified standard cellular processes, such as protein synthesis, transcription, and phosphorylation, as most represented in the 500 most equivalently expressed genes, which are rather common cellular processes. Macrophage-specific processes do not appear in the GO term list ( Table 2) .
Analysis of the 500 most equivalently expressed genes using Ingenuity Pathway Analysis (Ingenuity Systems, http://www. ingenuity.com) system resulted in a top 5 of networks with a network score of at least 20 ( Table 3 ). The top pathway was "Cellular assembly and Organization, Skeletal and Muscular System Development and Function and Tissue Morphology." The score is based on a P value calculation, which calculates the likelihood that the "network-eligible genes" that are part of a network, are found in that network by random chance alone. Remarkable are the networks involved in development, either embryonic or skeletal and muscular. Cancer processes are also present.
To investigate the feasibility of combining differential expression data and our measure of significant equivalence in pathway analysis, we submitted the differential expression data combined with the 500 most equivalently expressed genes to Ingenuity Pathway Analysis. We ascribed the genes a fold change code of 1 for the upregulated, Ϫ1 for the downregulated, and 0 for the equivalently expressed genes. The top 5 regulated networks are reported in Table 4 .
Combining all these expression data gave an interesting view on the processes involved in atherosclerotic plaque macrophages. As an example the number 1 ranked network is shown in Fig. 2A . As can be seen in this figure, XBP1, a protein involved in the unfolded protein response in ER stress, directly regulates a number of genes involved in ER function. Six of these genes are significantly upregulated in plaque macrophages (HERPUD1, GOPC, GOLGB1, ERO1LB, DANJC3, SEC61G), five genes are downregulated (GOSR2, RCN3, SRP68, SERP1, SEC61B), but there are also four genes involved in ER stress that remained unchanged (DAD1, STCH, SSR1, RABAC).
Macrophage-specific expression. To identify a more macrophage-specific subset of the equivalently expressed genes, we performed hierarchical clustering of the expression data of these genes in the Novartis human gene atlas dataset (42) . This dataset contains the expression profiles of 79 separate human body tissues (Supplemental Table S4 ) and thus can be used to subtract commonly expressed genes from our dataset. This procedure resulted in 200 strongly correlated genes with below-median expression levels across the human gene atlas. These genes were clustered with a correlation of r ϭ 0.68 (Fig. 3) and are shown in Supplemental Table S4 .
DISCUSSION
Here we present a new methodology of microarray data analysis that not only provides insight in shared molecular mechanisms or genomic signatures characteristic of a given cell type or condition but also aids in the identification of a set of marker genes that can be used for drug targeting and molecular imaging purposes. Additionally it is a suitable tool in studies in which adequate control groups are not readily available. Examples are the identification of features that are shared by a tumor and its metastases or are shared among all interleukin 1 receptor antagonist, a protein that binds to IL1 receptors (IL1R1) and inhibits the binding of IL1-␣ and IL1-␤; IL1A and IL1B mRNA levels were markedly reduced in peripheral blood mononuclear cells (PBMCs) from CAD patients after 6 mo of statin therapy, with a lesser reduction in IL1RN (4, 10, 51) 374 NOS3, eNOS regulates nitric oxide (NO) production in endothelial cells and thus regulates vasoconstriction; the PI3K-AKT pathway mediates the activation of eNOS, leading to increased NO production in endothelial cells; eNOSϪ/Ϫ mice have a reduced metabolic rate and accelerated weight gain compared with wild-type mice; eNOS has a role in progenitor cell recruitement (1, 14, 29) 245 APOC2 apolipoprotein C-II (apoC-II) is a necessary cofactor for the activation of lipoprotein lipase (LPL), the enzyme that hydrolyzes triglycerides in plasma and transfers the fatty acids to tissues; APOC2 deficiency is associated with premature vascular disease (8) 284
CXCL6, GCP-2 CXCL6 expression is induced by IL-1B and has chemoactractive functions on myeloid cells (48) 291 CCR7
this receptor is expressed in various lymphoid tissues and activates B and T lymphocytes; it has been shown to control the migration of memory T cells to inflamed tissues, as well as stimulate dendritic cell maturation; the chemokine (C-C motif) ligand 19 (CCL19/ECL) has been reported to be a specific ligand of this receptor (7, 31, 34) metastases of a particular tumor. Other applications are the identification of commonly expressed genes in disease, such as genes that are unchanged during plaque progression, the identification of genes that are equivalently expressed during cell (trans)differentiation between circulating precursor cells and their differentiated counterparts, or, as in our case, identification of gene expression profiles of a certain cell type regardless of the residential tissue.
Conventional inference statistics like a two-sided t-test for independent samples aims to detect a significant difference, Delta, with a null hypothesis which is formulated as H 0 : Delta ϭ 0 and a significance level ␣ that controls the type 1 error (i.e., incorrect rejection of the null hypothesis). Conversely, however, the absence of a significant difference does not imply that the null hypothesis is true. In this case the type 2 error (i.e., failing to reject the null hypothesis when it is false) is uncontrollable. In other words this set-up does not allow drawing conclusions on equivalence of the measurements. Such analysis would require a dedicated test to prove equality (19) .
Several measures have been taken to minimize false positives and optimize the sensitivity in our statistical model. First, by determining the per patient gene spread and using the maximum gene spread of all patients as a measure of expression equivalence, the power of biological replicates is optimally exploited. In this way a gene has to be equivalently expressed in all tissue macrophages within all four patients. Furthermore, we used intrapatient equivalence to exclude interpatient variability in our equivalence estimation. Thus a gene has to be equivalently expressed in all macrophages within a patient, but the expression levels may vary between patients. In this way the results are not influenced by possible systemic interpatient variance.
We showed the effects of the used ␣-levels on the dynamics of the test results. We concluded that a level of ␣ ϭ 0.05 was best suited for this data set; because the top 500 gene set overlaps with all other confidence intervals, it delivers an acceptable amount of weight to the technical variance and is less prone to the effects of an increase in claimed positives P value is an EASE score, a modified Fisher exact P value, for geneenrichment analysis. It ranges from 0 to 1. Fisher exact P value ϭ 0 represents perfect enrichment. Usually P value Ͻ0.05 to be considered strongly enriched in the annotation categories. % ϭ percentage of all genes. Top 5 of networks identified using Ingenuity Pathway Analysis on the equivalently expressed macrophage genes combined with the genes differentially in atherosclerotic plaque residing macrophages compared with human Kupffer cells and alveolar macrophages and splenic macrophages. compared with ␣ ϭ 0.025 and ␣ ϭ 0.005. When using a level of ␣ ϭ 0.05, the chance of the gene spread being larger than the calculated one is 5% based on technical variation. This implies that with increasing confidence intervals genes with high technical errors that lie at the upper or lower end of the gene spread spectrum are ranked relatively lower than genes with small technical errors. This effect is reduced by the correction for gene intensity that is normalized to the average common reference intensity. This results in a ranking based on the (shifted) relative gene spread. Ranking the genes based on the distance to the cut-off line does not influence the composition of the list of equivalently expressed genes but does influence the ranking of the genes by adding more weight to the intensity. Ranking the genes on relative gene spread in turn strongly prefers low gene spread over high gene intensity. We believe ranking the genes on the distance to the cut-off function is the best method, because it renders the ranking dependent on the slope of the cut-off line, which is in turn dependent on the effects of permuting the data.
During our analysis we identified a discordance between the results of differential expression analysis of individual arrays using the Rosetta error model and our method of expression equivalence. For example the CCL19/CCL21 receptor CCR7, a receptor mostly involved in dendritic cell maturation, activation of B and T lymphocytes, and migration of memory T-cells (21, 36, 54) , is present in the 500 most equivalently expressed genes (rank 367). However, in two out of three single tissue comparisons in patient 1, this gene is found to be upregulated. This is in plaque macrophages compared with liver as well as spleen macrophages. Conversely in patient 2, CCR7 is differentially downregulated in the same comparisons. In this model the inference of a comparison within a single patient is based solely on technical replicates, implying that the technical reproducibility of the measurement technique determines the inference instead of the biological variation (2). The technical variation of CCR7 appears to be at such a low level that even the smallest change in expression is identified as significant. These minute changes might be statistically significant but are most likely not biologically relevant. In our model two tissues that are at the boundaries of the gene spread might be annotated as significantly different by an error model like Rosetta's in a single comparison; however, taking into account the other tissues measured, the overall expression is significantly equivalent among tissues.
The gene ontology clusters we identified mostly consist of processes involved in transcription, translation, and other standard cellular processes, such as catalytic activity, membrane components, and transport proteins. We did not find any unexpected or revealing clusters. The knowledge-based networks created by Ingenuity, however, show similar results with the exception that the top biological functions concern more macrophage-like functions, such as cell morphology, connective tissue disorders, lipid metabolism, and cellular movement.
Combining the equivalence data with the differential expression data of plaque-residing macrophages compared with human Kupffer cells and alveolar and splenic macrophages really brings the Ingenuity pathway analysis to its full potential. Due to the fact that the software can distinguish between upregulated and downregulated genes and also incorporates nondifferentially expressed genes into its networks, a great overview of gene interactions and cellular processes involved in plaqueresiding macrophages is generated. Figure 2A is an example of many interesting networks generated by this combination. This network was not detected using just the up-and downregulated genes.
As can be seen in this figure, XBP1 is equivalently expressed in all macrophages. XBP1 is a transcription factor that gets alternatively spliced by IRE1 upon ER stress and activation of the unfolded protein response (UPR) resulting in two versions of XBP1, an unspliced version XBP1(U) and a spliced version XBP1(S). The spliced version XBP1(S) has higher transcriptional activator activity and is known to upregulate Herpud1, Gopc, Stch, Ssr1, Gosr2, Golgb1, Rcn3, Rabac1, Srp68, Sec61b, Sec61g, Ero1-␤, and DAD1 in murine NIH/ 3T3 cells (6, 41, 56) . Although plaque-residing macrophages are known to be prone to lipid loading-induced ER stress, we see no regulation of XBP1 mRNA in these macrophages compared with their non-ER-stressed counterparts. But we do see differential regulation of a number of its effector genes. This controversy can be explained by the posttranscriptional regulation of XBP1(U) into XBP1(S) upon ER stress without influencing the transcription of XBP1 mRNA.
This example clearly stresses the additional value of including equivalence data in microarray experiments, especially when it is intended to perform pathway analysis. The potential uses of the equivalence data will increase with specialized tools optimized to handle the equivalence data correctly.
Next to the pathway analysis we found a number of very remarkable genes given their alleged functional role in dedicated macrophage subsets, such as IL1 receptor antagonist (IL1RN), MHC-related CD1C, and ProsaPiP1, that have significantly equivalent expression levels in macrophages from all four tissues. ProSAP-interacting protein 1 (ProSAPiP1), a protein that interacts with ProSAP/shank scaffolding protein in the postsynaptic density, has only been found in brain during late neuronal development (52) and in secretory granules of hypophyseal and pancreatic endocrine cells (32) . These findings are supported by our hierarchical clustering data. Interestingly this is our top ranked gene, regardless of the chosen level of ␣ (0.5-10%) or the chosen ranking (relative gene spread or distance to the cut-off function), indicating a relatively high expression level in all macrophages with a small variation in expression levels over different residential tissues.
Macrophage content and activity are among the key targets of atheroma imaging because inflammation within atheromata could potentially distinguish between vulnerable and stable states (40) . Current studies using MRI and ultrasmall particles of iron oxide (23, 37, 38, 45 53a) or gadolinium-loaded micelles targeted at macrophage scavenger receptor, a macrophage-specific cell surface protein, which is overexpressed on atherosclerotic macrophages and foam cells, are exploring the possibilities of implementing macrophage imaging as a diagnostic tool for atherosclerotic disease (25) (26) (27) 46) . Genes like ProSAPiP1 are putative markers for imaging of atherosclerotic plaques, not only because of the high expression levels and the probable extracellular exposure, but also because it is always expressed in every macrophage no matter what circumstance the macrophage is in and thus also in every macrophagecontaining plaque. Even though plaque macrophage specificity is not demonstrated, the potential use of targeted imaging probes that are administered through the blood and aimed at these type of proteins will result in a bright spot at the location of a macrophage-rich plaque (50) .
Another approach to identify putative macrophage imaging markers is the hierarchical clustering we performed using the Novartis human gene atlas dataset. This method allows the identification of a gene set that has below-median expression across the human gene atlas but has high and stable expression levels in macrophages. ProsaPiP1 was not among the 200 genes with low expression levels in the tested tissues. This is due to the high expression of ProsaPiP1 in the neural tissues. IL1RN, ABCG4, and NOS3, however, were among the 200 genes and thus also might be putative macrophage imaging targets. Unfortunately the gene atlas did not contain endothelium, which would probably have ruled out NOS3.
Macrophage markers are by definition highly expressed on macrophages and often involved in macrophage functionality. Of all proposed macrophage markers (7C3, 25F9, 27E10, CPM, Cathepsin K, Chitotriosidase, CD14, CD68, CD163, sCD163, CSF-1R, ED-1, ED-2, EMR1, F4/80, Factor XIII-A, Ferritin, HAM-56, Ki-M1P, Lysozyme M, MAC-1/MAC-3, MRP 14, RFD7/RFD9, RM3/1) only the macrophage marker CD68 was equivalently expressed in all tissue macrophages in our study. This is not unexpected, because our test does not explore macrophage-specific expression. Rather, it aims at identifying genes whose expression is independent of the residential tissue, while the levels of cytokine production and inflammatory receptor expression are very dependent on the specific function of a macrophage in that particular tissue. The selection of all macrophages in this study was based on CD68 positivity, thus finding CD68 forms a proof of concept and also implies that the CD68 levels are very stable throughout the CD68-positive macrophage population.
Another set of genes that is expected in the outcome of an equivalence test of gene expression are the housekeeping genes. We checked for the contribution of housekeeping genes to our top 500 equivalently expressed genes by comparing the top 500 with the list of housekeeping genes published by Eisenberg and Levanon (12) . Out of 575 listed housekeeping genes, 35 were among the top 500 equivalently expressed macrophage genes, meaning that 7% of the equivalently expressed macrophage genes are housekeeping genes. Interestingly oxidative stress network genes XBP1, DAD1, and RABAC were among these 35 genes.
In this study we applied the equivalence test on a set of duplicate arrays of four types of tissue residing macrophages in four patients. We then combined this data with data obtained from differential analysis. In all, we now have 2,114 (11.3%) genes form a total of 18,659 measured genes of which we can, with a certain degree of confidence, say that they are either differentially or equivalently expressed. It appears that power is of the essence here. With n ϭ 4, power appears insufficient to provide insight in the regulation of Ͼ11.3% of all measured genes. Higher sample sizes will increase power and thus the percentage of genes of which we can state with for example 95% confidence that they are unchanged or differentially expressed.
The method described here is not yet foolproof. It still needs further validation and optimization and probably can be perfected in several ways, to increase the sensitivity and reduce false positive rates. We are aware of the limitations of our study, such as the small number of patients and the small number of tissue macrophage types but want to stress the importance of developing a valid equivalence test for microarray data.
Given the impact of equivalence testing for microarray data we envision broad application in many different research fields ranging from oncology to atherosclerosis research. The proposed algorithm is, in combination with hierarchical clustering, a powerful tool in the identification of marker and signature genes, which are eagerly awaited for the development of molecular imaging techniques. It aids in extended feature extraction from standard microarray studies and improves pathway analysis by combining it with differentially expressed gene sets. Finally it creates opportunities to study mechanisms that lack readily available controls. Thus microarray equivalence testing offers an indeclinable opportunity to extend the data mining options for microarray studies.
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